Determination of Neurophysiological P300 and P50 in Patients with Schizophrenia at a Tertiary Hospital in Sokoto, Nigeria
DOI:
https://doi.org/10.4314/ajtmbr.v7i2.7Keywords:
Schizophrenia Neurophysiological P300Abstract
Introduction: Schizophrenia is a severe and complex mental disorder. It currently lacks an objective biological diagnostic test. Neurophysiological markers like P300 and P50 event-related potentials have shown some diagnostic usefulness in previous studies. However, very few of these studies have been done among Africans. The objective of the study was to evaluate neurophysiological P300 and P50 event related potentials in 70 schizophrenia patients and 70 healthy controls at a tertiary psychiatric hospital in Sokoto, Nigeria.
Materials and Methods: The instruments used were the Electroencephalogram (EEG) machine, laptop with installed auditory P300 and P50 tones, headphones, Positive and Negative Syndrome Scale (PANSS).
Results: Schizophrenia patients were significantly associated with higher amplitude of P300 and prolonged P300 peak latency auditory event-related potential compared to healthy controls (U= 1077.000, P=<0.001 and U= 1191.000, P=<0.001) respectively. Schizophrenia patients were also significantly more associated with higher P50 amplitude ratio (U= 1342.500, P=<0.001). The P300 even trelated amplitude had the highest area under the curve of 0.78. P300 peak latency was the most specific (Specificity=0.93) while P50 ratio was most sensitive (Sensitivity=0.76). The determined cut-off points for P300 amplitude, P300 peak latency, and P50 ratio were 6.84µv, 445ms, and 0.89 respectively. There was a significant positive correlation between P50 ratio and age of participants among schizophrenia patients (rs=0.29, P=0.02).
Conclusion: The study has determined the cut-off points for P300 and P50 neurophysiological markers in patients with schizophrenia. These will serve as an adjunct for diagnosis and for forensic purposes in these patients. Further studies including neuroimaging, biochemical, and genetic aspects are recommended in African countries.
References
Smith T, Horwa th E, Cou r nos F. Schizophrenia and other psychotic disorders. New York, NY: Oxford University Press; 2010 Apr 28.
Greenwood TA, Shutes-David A, Tsuang DW. Endophenotypes in schizophrenia: dig ging de epe r to identif y g ene ti c mechanisms. Journal of psychiatry and brain science. 2019;4(2).
Owens E, Bachman P, Glahn DC, Bearden CE. Electrophysiological endophenotypes for schizophrenia. Harvard review of psychiatry. 2016 Mar;24(2):129.
Kendler KS, Neale MC. Endophenotype: a conceptual analysis. Molecular psychiatry. 2010 Aug;15(8):789-97.
Cohen MX. Where does EEG come from and what does it mean?. Trends in neurosciences. 2017 Apr 1;40(4):208-18.
Del Re EC, Bergen SE, Mesholam-Gately RI, Niznikiewicz MA, Goldstein JM, Woo TU, Shenton ME, Seidman LJ, McCarley RW, Pe tr y s h e n TL . An a l y sis o f s ch i z o p h r e n i a -r e l a t e d g e n e s a n d electrophysiological measures reveals ZNF804A association with amplitude of P3 0 0 b e l i c it e d by n ove l s o u n d s. Translational psychiatry. 2014 Jan;4(1):e346.
Earls HA, Curran T, Mittal V. A metaanalytic review of auditory event-related potential components as endophenotypes for schizophrenia: perspectives from firstdegree relatives. Schizophrenia bulletin 2016 Nov 1;42(6):1504-16.
Ba n e a OC, Pe g o l o E, M a r c u S, Friðriksdóttir R, Ívarsson E, Jónasson AD, J ó n a ss o n VD, Ma g nu s d ó ttir BB, Haraldsson M, Wassermann E, Gargiulo P. P50 and P300 Event Related Potentials in Patients with Schizophrenia Recorded from High-Density EEG. In Mediterranean Conference on Medical and Biological Engineering and Computing 2019 Sep 26 (pp. 1071-1077). Springer, Cham.
Sasidharan A, Nair AK, Marigowda V, Lukose A, John JP, Kutty BM. Simultaneous assessment of P50, MMN, ERN and P300 event related potentials among patients with Schizophrenia–an exploratory study. BioRxiv. 2019 Jan 1:837815.
Hedges D, Janis R, Mickelson S, Keith C, Bennett D, Brown BL. P300 amplitude in Alzheimer's disease: a meta-analysis and meta regression. Clinical EEG and neuroscience. 2016 Jan;47(1):48-55.
Lijffijt M, Moeller FG, Boutros NN, Steinberg JL, Meier SL, Lane SD, Swann AC. Diminished P50, N100 and P200 auditory sensory gating in bipolar I disorder. P s y c h i a tr y r e s e a r c h . 2 0 0 9 M a y 30;167(3):191-201.
Thoma L, Rentzsch J, Gaudlitz K, Tänzer N, Gallinat J, Kathmann N, Ströhle A, Plag J. P50, N100, and P200 sensory gating in panic disorder. Clinical EEG and Neuroscience. 2020 Sep;51(5):317-24.
Sinha SR, Sullivan LR, Sabau D, Orta DS, Dombrowski KE, Halford JJ, Hani AJ, Drislane FW, Stecker MM. American clinical neurophysiology society guideline 1: minimum technical requirements for performing clinical electroencephalography. The Neurodiagnostic Journal. 2016 Oct 1;56(4):235-44.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia bulletin. 1987 Jan 1;13(2):261-76.
Qiu YQ, Tang YX, Chan RC, Sun XY, He J. P300 aberr a tion in first-episode schizophrenia patients: a meta-analysis. PLoS One. 2014 Jun 16;9(6):e97794.
Sullivan LM. Essentials of biostatistics in public health. Jones & Bartlett Learning; 2017 Feb 14.
Hakulinen C, McGrath JJ, Timmerman A, Skipper N, Mortensen PB, Pedersen CB, Agerbo E. The association between earlyonset schizophrenia with employment, income, education, and cohabitation status: nationwide study with 35 years of follow-up. Soc i a l Ps y chi a tr y and Ps y chi a tri c Epidemiology. 2019 Nov;54(11):1343-51.
Dickson H, Laurens KR, Cullen AE, Hodgins S. Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychological medicine. 2012 Apr;42(4):743-55.
Adewuya AO, Makanjuola RO. Subjective quality of life of Nigerian schizophrenia patients: sociodemographic and clinical correlates. Acta Psychiatrica Scandinavica. 2009 Aug;120(2):160-4.
Gupta M, Bassett E, Iftene F, Bowie CR. Functional outcomes in schizophrenia: u n d e rst a n d i n g t h e c omp e t e n c e - performance discrepancy. Journal of psychiatric research. 2012 Feb 1;46(2):205-11.
Wang H, Zhang M, Chen X, Lou F, Liang J, Chen C, Shi T, Lu Q. P50 auditory sensory gating in first onset schizophrenics and normal healthy adults. Frontiers of medicine in China. 2007 Oct;1(4):429-32.
Shen CL, Chou TL, Lai WS, Hsieh MH, Liu CC, Liu CM, Hwu HG. P50, N100, and P200 auditory sensory gating deficits in schizophrenia patients. Frontiers in Psychiatry. 2020 Aug 27;11:868.
Vlcek P, Bob P, Raboch J. Sensory disturbances, inhibitory deficits, and the P 5 0 w a v e i n s c h i z o p h r e n i a . Neuropsychiatric disease and treatment. 2014;10:1309.
Bencherif M, Stachowiak MK, Kucinski AJ, Lippiello PM. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple n e u r o tr a n smitt e r hy p o t h e s e s o f schizophrenia. Medical Hypotheses. 2012 May 1;78(5):594-600.
Freedman R. α7-nicotinic acetylcholine r e c e p t o r a g o n ists f o r c o g n i t i v e enhancement in schizophrenia. Annual review of medicine. 2014 Jan 14;65:245-61.
Polich J. Updating P300: an integrative theor y of P3 a and P3b. Cl ini c a l neurophysiology. 2007 Oct 1;118(10):2128- 48.
van Dinteren R, Arns M, Jongsma ML, Kessels RP. P300 development across the lifespan: a systematic review and metaanalysis. PloS one. 2014 Feb 13;9(2):e87347.
Jeon YW, Polich J. Metaanalysis of P300 and schizophrenia: Patients, paradigms, and practical implications. Psychophysiology. 2003 Sep;40(5):684-701.
Sahoo S, Malhotra S, Basu D, Modi M. Auditory P300 event related potentials in acute and transient psychosis—Comparison with schizophrenia. Asian Journal of Psychiatry. 2016 Oct 1;23:8-16.
Park EJ, Jin YT, Kang CY, Nam JH, Lee YH, Yum MK, Han SI, Jeon YW. Auditory and visual P300 in patients with schizophrenia and controls: Stimulus modality effect size differences. Clinical Psychopharmacology and Neuroscience. 2005 Feb 1;3(1):22-32.
Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographicmodulators in COGS-2. Schizophrenia research. 2015 Apr 1;163(1-3):53-62.
Winterer G, Egan MF, Raedler T, Sanchez C, Jones DW, Coppola R, Weinberger DR. P300 and genetic risk for schizophrenia. Archives o f g e n e r a l p s y ch i a tr y. 2 0 0 3 Nov 1;60(11):1158-67.
Benson PJ, Beedie SA, Shephard E, Giegling I, Rujescu D, Clair DS. Simple viewing tests can detect eye movement abnormalities that distinguish schizophrenia cases from controls with exceptional accuracy. Biological psychiatry. 2012 Nov 1;72(9):716-24.
Schröder E, Kajosch H, Verbanck P, Kornreich C, Campanella S. Methodological considerations about the use of bimodal oddball P300 in psychiatry: topography and reference effect. Frontiers in Psychology. 2016 Sep 21;7:1387.
Gold JM, Kool W, Botvinick MM, Hubzin L, August S, Waltz JA. Cognitive effort avoidance and detection in people with schizophrenia. Cognitive, affective, & b e h a v i o r a l n e u r o s c i e n c e . 2 0 1 5 Mar;15(1):145-54
Fuentes-Claramonte P, López-Araquistain L, Sarró S, Sans-Sansa B, Ortiz-Gil J, Maristany T, Salvador R, McKenna PJ, Pomarol-Clotet E. Brain functional correlates of formal thought disorder in s c h i z o p h r e n i a : e x a m i n i n g t h e fr o n t a l / d y s e xe c u tive hy p o t h e sis.P s y c h o l o g i c al M e d i c i n e . 2 0 2 1 Oct;51(14):2446-53.
Baving L, Rockstroh B, Rößner P, Cohen R, Elbert T, Roth WT. Event-related potential correlates of acquisition and retrieval of verbal associations in schizophrenics and controls. Journal of Psychophysiology. 2000;14(2):87.
Frodl-Bauch T, Bottlender R, Hegerl U. N e u r o c h e m i c a l s u b st r a t e s a n d neuroanatomical generators of the event related P300. Neuropsychobiolog y. 1999;40(2):86-94.
Schutte I, Deschamps PK, van Harten PN, Kenemans JL. Dopamine r g i c and noradrenergic manipulation of anticipatory reward and probability event-related potentials. Psychopharmacology. 2020 Jul;237(7):2019-30.
Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures A World Health Organization Ten-Country Study. Psychological Medicine monograph supplement. 1992;20:1-97.
Kulhara P. Outcome of schizophrenia: some transcultural observations with particular reference to developing countries. European Archives of Psychiatry and C l i n i c a l N e u r o s c i e n c e . 1 9 9 4 Dec;244(5):227-35.
Harrison G, Hopper KI, Craig T, Laska E, Siegel C, Wanderling JO, Dube KC, Ganev K, Giel R, Der Heiden WA, Holmberg SK. Recovery from psychotic illness: a 15-and 25-year international follow-up study. The British journal of psychiatry y. 2001 Jun;178(6):506-17.
Hassan WA, Darweesh AE, Abdel-Rahman AA, Ahmad HE, Hassaan SH, Noaman MM, Fahmy IF. P300 cognitive assessment in patients with first-episode psychosis: a prospective case-control study. Middle East Current Psychiatry. 2020 Dec;27(1):1-8.
Mandr eka r JN. Re c e ive r ope r a ting characteristic curve in diagnostic test assessment. Journal of Thoracic Oncology. 2010 Sep 1;5(9):1315-6.
Peters RM, Gjini K, Templin TN, Boutros NN. A statistical methodology to improve accuracy in differentiating schizophrenia patients from healthy controls. Psychiatry research. 2014 May 30;216(3):333-9.
Johannesen JK, O'Donnell BF, Shekhar A, McGrew JH, Hetrick WP. Diagnostic s p e c i fi c it y o f n e u r o p hy si o l o g i c a l endophenotypes in schizophrenia and bipolar disorder. Schizophrenia bulletin. 2013 Nov 1;39(6):1219-29.
Chun J, Karam ZN, Marzinzik F, Kamali M, O'Donnell L, Tso IF, Manschreck TC,McInnis M, Deldin PJ. Can P300 distinguish among schizophrenia, schizoaffective and bipolar I disorders? An ERP study of response inhibition. Schizophrenia research. 2013 Dec 1;151(1-3):175-84.
Power M, Fell G, Wright M. Principles for high-quality, high-value testing. BMJ Evidence-Based Medicine. 2013 Feb 1;18(1):5-10.
Turetsky BI, Calkins ME, Light GA, Olincy A , R a d a n t A D, S w e r d l o w N R . Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophrenia bulletin. 2007 Jan 1;33(1):69-94.
Petersen L, Sørensen TI. Studies based on the Danish Adoption Register: schizophrenia, BMI, smoking, and mortality in perspective.Scandinavian journal of public health. 2011
Jul;39(7_suppl):191-5.
Yu YW, Chen TJ, Chen MC, Tsai SJ, Lee TW. Effect of age and global function score on schizophrenic p300 characteristics. Neuropsychobiology. 2005;51(1):45-52.
Bourisly AK. Effects of aging on P300 between late young-age and early middleage adulthood: an electroencephalogram event related potential study. NeuroReport. 2016 Sep 28;27(14):999-1003.
Juckel G, Karch S, Kawohl W, Kirsch V, Jäger L, Leicht G, Lutz J, Stammel A, Pogarell O, Ertl M, Reiser M. Age effects on the P300 potential and the corresponding fMRI BOLD-signal. Neuroimage. 2012 May 1;60(4):2027-34.
Chang WH, Chen KC, Yang YK, Chen PS, Lu RB, Yeh TL, Wang CS, Lee IH. Association between auditory P300, psychopathology, and memory function in drug-naïve schizophrenia. The Kaohsiung Journal of Medical Sciences. 2014 Mar 1;30(3):133-8.
Ringel TM, Heidrich A, Jacob CP, Fallgatter AJ. Sensory gating deficit in a subtype of chronic schizophrenic patients. Psychiatry research. 2004 Mar 15;125(3):237-45.
Louchart-de la Chapelle S, Levillain D, Ménard JF, Van der Elst A, Allio G, Haouzir S, Dollfus S, Campion D, Thibaut F. P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia. Psychiatry Research. 2005 Jul 15;136(1):27- 34.
Thoma RJ, Hanlon FM, Moses SN, Ricker D, Huang M, Edgar C, Irwin J, Torres F, Weisend MP, Adler LE, Miller GA. M50 sensory gating predicts negative symptoms in schizophrenia. Schizophrenia research.2005 Mar 1;73(2-3):311-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 African Journal of Tropical Medicine and Biomedical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
COPYRIGHT LICENSE
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
International Public License
Section 1 -- Definitions.
a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.
b. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.
c. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.
d. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.
e. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.
f. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.
g. Licensor means the individual(s) or entity(ies) granting rights under this Public License.
h. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.
i. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.
j. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.
k. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.
Section 2 -- Scope.
a. License grant.
- Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:
a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and
b. produce and reproduce, but not Share, Adapted Material for NonCommercial purposes only.
-
Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.
-
Term. The term of this Public License is specified in Section 6(a).
-
Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a)(4) never produces Adapted Material.
-
Downstream recipients.
a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.
b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.
- No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).
b. Other rights.
-
Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
-
Patent and trademark rights are not licensed under this Public License.
-
To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.
Section 3 -- License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following conditions.
a. Attribution.
- If You Share the Licensed Material, You must:
a. retain the following if it is supplied by the Licensor with the Licensed Material:
i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);
ii. a copyright notice;
iii. a notice that refers to this Public License;
iv. a notice that refers to the disclaimer of warranties;
v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;
b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and
c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.
For the avoidance of doubt, You do not have permission under this Public License to Share Adapted Material.
-
You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.
-
If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.
Section 4 -- Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:
a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only and provided You do not Share Adapted Material;
b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and
c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.
Section 5 -- Disclaimer of Warranties and Limitation of Liability.
a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.
b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.
c. The disclaimer of warranties and
limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.
Section 6 -- Term and Termination.
a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.
b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:
-
automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or
-
upon express reinstatement by the Licensor.
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.
c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.
d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.
Section 7 -- Other Terms and Conditions.
a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.
b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.
Section 8 -- Interpretation.
a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.
b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.
c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.
d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.
How to Cite
